RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
TEN is experiencing a cyclical upswing with revenue surging 54.4% in 2026Q2 and gross margin expanding to 46.8%, driven by favorable charter rates. However, the reported net income of $139.3M in that quarter includes significant non-operating gains, which may ...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 10, 2026 | $3.14+7.2% vs $2.93 | $246M+3.1% vs $239M |
Q2 2026 May 21, 2026 | $2.72+31.4% vs $2.07 | $223M+6.9% vs $209M |
Q2 2026 Mar 6, 2026 | $1.70+58.9% vs $1.07 | $195M+12.9% vs $173M |
Q4 2025 Nov 20, 2025 | $1.05+36.4% vs $0.77 | $186M+14.4% vs $163M |
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSOÂ (osimertinib) demonstrated a sustained, clinically meaningful overal
Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
Tsakos Energy Navigation Limited (TEN) Q2 2026 Earnings Call Transcript
Benchmark TEN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tsakos Energy Navigation Limited (TEN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $48.27 | $1.45B | 10.85 | -0.67% | 20.15% | 8.86% | 4.19% | |
| $95.60 | $3.31B | 9.47 | -22.58% | 51.35% | 27.73% | — | |
| $103.95 | $5.15B | 16.69 | -11.38% | 61.86% | 37.04% | — | |
| $21.39 | $3.44B | 16.33 | -13.04% | 65.54% | 39.55% | — | |
| $82.33 | $4.1B | 11.71 | -24.58% | 67.16% | 24.51% | — | |
| $7.66 | $1.62B | 132.07 | -16.39% | 33.2% | 26.85% | — |
Tsakos Energy Navigation Limited (TEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tsakos Energy Navigation Limited (TEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 17, 2022·SEC
Nov 14, 2022·SEC
Nov 7, 2022·SEC
Feb 24, 2022·SEC
Get notified when TEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tsakos Energy Navigation Limited (TEN) stock FAQ — growth, dividends, profitability & financials explained
Tsakos Energy Navigation Limited (TEN) reported $910.9M in revenue for fiscal year 2025. This represents a 86% decrease from $6.65B in 1996.
Tsakos Energy Navigation Limited (TEN) saw revenue decline by 0.7% over the past year.
Yes, Tsakos Energy Navigation Limited (TEN) is profitable, generating $261.9M in net income for fiscal year 2025 (20.1% net margin).
Yes, Tsakos Energy Navigation Limited (TEN) pays a dividend with a yield of 4.19%. This makes it attractive for income-focused investors.
Tsakos Energy Navigation Limited (TEN) has a return on equity (ROE) of 8.9%. This is below average, suggesting room for improvement.
Tsakos Energy Navigation Limited (TEN) had negative free cash flow of $575.2M in fiscal year 2025, likely due to heavy capital investments.